QuidelOrtho (NASDAQ:QDEL) Releases Earnings Results

Key Points

• QuidelOrtho reported quarterly EPS of $0.31, beating analyst estimates of $0.20 by $0.11, while revenue of $618.9 million fell short of the $627.8 million consensus.
• The company posted a negative net margin of 39.2%; its shares rose 0.4% to $14.09 in midday trading.
• Analyst sentiment remains cautious: MarketBeat’s consensus rating is “Reduce,” with a $13.62 average price target.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported $0.31 EPS for the quarter, topping analysts' consensus estimates of $0.20 by $0.11, FiscalAI reports. QuidelOrtho had a positive return on equity of 4.88% and a negative net margin of 39.20%. The company had revenue of $618.90 million for the quarter, compared to analysts' expectations of $627.83 million.

QuidelOrtho Stock Up 0.4%

Shares of NASDAQ:QDEL traded up $0.06 during midday trading on Tuesday, reaching $14.09. The company had a trading volume of 3,536,049 shares, compared to its average volume of 1,783,132. The stock has a market capitalization of $966.22 million, a P/E ratio of -0.91 and a beta of 0.79. The stock's fifty day moving average price is $12.74 and its 200-day moving average price is $16.38. The company has a debt-to-equity ratio of 1.43, a current ratio of 1.39 and a quick ratio of 0.76. QuidelOrtho has a one year low of $9.92 and a one year high of $35.58.

Wall Street Analysts Forecast Growth

QDEL has been the topic of several analyst reports. Zacks Research upgraded QuidelOrtho from a "strong sell" rating to a "hold" rating in a report on Friday, October 9th. Citigroup upped their price target on QuidelOrtho from $13.00 to $18.00 and gave the stock a "neutral" rating in a report on Wednesday, July 8th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of QuidelOrtho in a research report on Thursday, October 15th. Four analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, QuidelOrtho presently has an average rating of "Reduce" and a consensus target price of $13.62.

QuidelOrtho Company Profile

QuidelOrtho Corporation NASDAQ: QDEL is a global in vitro diagnostics company formed through the combination of Quidel Corporation and Ortho Clinical Diagnostics, a transaction completed in 2022. The company develops, manufactures and markets diagnostic technologies used to detect disease, guide treatment decisions and support blood-transfusion safety.

Its portfolio includes rapid immunoassays, molecular testing systems, clinical chemistry and immunohematology products, as well as laboratory automation solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.